References
- Pearlman R., Bewley T. A. Stability and characterization of human growth hormone. Stability and Characterization of Protein Drugs: Case Histories, Y. J. Wang, R. Pearlman. Plenum Press, New York 1993; 1–58
- Becker G., Bowsher R., Mackellar W., Poor M., Tackitt P., Riggin R. Chemical, physical, and biological characterization of a dimeric form of biosynthetic human growth hormone. Biotechnol. Appl. Biochem 1987; 9: 478–487
- Eckhardt B. M., Oeswein J. Q., Bewley T. A. Effect of freezing on aggregation of human growth hormone. Pharm. Res 1991; 8: 1360–1364
- Charman S. A., Mason K. L., Charman W. N. Techniques for assessing the effects of pharmaceutical excipients on the aggregation of porcine growth hormone. Pharm. Res 1993; 10: 954–962
- Katakam M., Bell L. N., Banga A. K. Effect of surfactants on the physical stability of recombinant human growth hormone. J. Pharm. Sci 1995; 84: 713–716
- Sato S., Ebert C. D., Kim S. W. Prevention of insulin self-association and surface adsorption. J. Pharm. Sci 1983; 72: 228–232
- Kirsch L. E., Riggin R. M., Gearhart D. A., Lefeber D. S., Lytle D. L. In-process protein degradation by exposure to trace amounts of sanitizing agents. J. Parenter. Sci Technol 1993; 47: 155–160
- Mantyh P. W., Ghilardi J. R., Rogers S., Demaster E., Allen C. J., Stimson E. R., Maggio J. E. Aluminum, iron and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J. Neurochem 1993; 61: 1171–1174
- Sluzky V., Tamada J. A., Klibanov A. M., Langer R. Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc. Natl. Acad. Sci. USA 1991; 88: 9377–9381
- Kosen P. A. Disulfide bonds in proteins. Stability of Protein Pharmaceuticals. Part A: Chemical Physical Pathways of Protein Degradation, T. J. Ahern, M. C. Manning. Plenum, New York 1992; 352–354
- Wade A., Weller P. J. Handbook of Pharmaceutical Excipients. American Pharmaceutical Association, Washington, DC 1994
- BASF Wyandotte Corp. Technical Data on Pluronic® Polyols No. OS796. Parsippany, NJ 1975; 1–11
- Johnston T. P., Miller S. C. Toxicological evaluation of poloxamer vehicles for intramuscular use. J. Parenter. Sci. Technol 1985; 39: 83–88
- Johnston T. P., Punjabi M. A., Froelich C. J. Sustained delivery of interleukin-2 from a Poloxamer 407 gel matrix following intraperitoneal injection in mice. Pharm. Res 1992; 9: 425–434
- Fults K. A., Johnston T. P. Sustained release of urease from a poloxamer gel matrix. J. Parenter. Sci. Technol 1990; 44: 58–65
- Wang P., Johnston T. P. Enhanced stability of two model proteins in an agitated solution environment using Poloxamer 407. J. Parenter. Sci. Technol 1993; 47: 73–81
- Oeswein J. Q., Daugherty A. L., Cornovaca E. J., Moore J. A., Gustafson H. M., Eckhardt B. M., Fichs H. J., Keller G., Patton J. S. Aerosolization of protein pharmaceuticals. Proceedings of the Second Respiratory Drug Delivery Symposium, R. N. Dalby, R. Evans. Continuing Pharmacy Education, University of Kentucky, 1991; 14–49
- Mumunthaler M., Hsu C. C., Pearlman R. Feasibility study on spray-drying protein pharmaceuticals: Recombinant human growth hormone and tissue-type plasminogen activator. Pharm. Res 1994; 11: 12–20
- Thurow H., Geisen K. Stabilization of dissolved proteins against denaturation at hydrophobic interfaces. Diabetologia 1984; 27: 212–218